Chiu CY, Chen CJ, Wong KS. Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community–acquired pneumonia. J Microbiol Immunol Infect 2015;48:51–56.

Miao X, Zhou J, Li J, Liao Y, Zheng Y. Chinese medicine in inhalation therapy: a review of clinical application and formulation development. Curr Pharm Des 2015;21:3917–3931.

Huang HH, Zhang YY, Wang F. Epidemiological study of adult community–acquired pneumonia infected with mycoplasma pneumonia and chlamydia pneumonia in Asia. Infect Chemother 2008;8:89–92.

Wattanathum A, Boonyongsunchai P, Palwatwichai A. Chlamydia pneumoniae in community acquired pneumonia. J Med Assoc Thai 2001;84:69–74.

Chan CH, Cohen M, Pang J. A prospective study of community–acquired pneumonia in Hong Kong. Chest 1992;101:442–446.

Okazaki N, Narita M, Yamada S. Characteristics of macrolide resistant mycoplasma pneumonia strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001;45:617–620.

Liu Y, Ye X, Zhang H. Antimicrobial susceptibility of mycoplasma pneumonia isolates and molecular analysis of macrolide resistant strains from Shanghai, China. Antimicrob Agents Chemother 2009;53:2160–2162.

Dow ell SF, Peeling RW, Boman J. Standardizing chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevent ion (USA) and the Laboratory Centre for disease Control (Canada). Clin Infect Dis 2001;33:492–503.

Mu KJ, He QY, eds. Lungs infection. Beijing: Beijing Medical University, Join Publishing House of Beijing Union University; 1996:390.

Li YG, Ai L. Mycoplasma pneumoniae of extra–pulmonary complications in 60 cases. Pediatr Clin Pract Mag (Chin) 2002;17:411.